US 9,809,597 B2
Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
Ritwik Burai, West Bengal (IN); Hilal Lashuel, Ecublens (CH); Vidhu Mathur, Mountain View, CA (US); and Anton Wyss-Coray, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Aug. 19, 2016, as Appl. No. 15/241,821.
Claims priority of provisional application 62/207,903, filed on Aug. 20, 2015.
Prior Publication US 2017/0050967 A1, Feb. 23, 2017
Int. Cl. C07D 473/18 (2006.01); A61K 45/06 (2006.01); A61K 31/52 (2006.01)
CPC C07D 473/18 (2013.01) [A61K 31/52 (2013.01); A61K 45/06 (2013.01)] 25 Claims
 
1. A compound having the formula:

OG Complex Work Unit Drawing
or a pharmaceutically acceptable salt thereof, wherein R is a propanethiol, 2-[(2-Amino-6-{2- [2-(2-ethoxyethoxy)ethoxy]ethoxy }-6,9-dihydro- 1H-purin-9-yl)methoxy]-1,3-propanediol, or 2-({2-Amino-6[3-(propyldithio)propoxy]-6,9-dihydro-1H-purin-9-yl}methoxy)-1,3-propanediol.